Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes

Drug Metabolism and Disposition

Volumn 27, Issue 11, 1999, Pages 1350-1359

  Obach, R Scott ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; AMOBARBITAL; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; CHLORPROMAZINE; CLOZAPINE; DESIPRAMINE; DIAZEPAM; DICLOFENAC; DILTIAZEM; DIPHENHYDRAMINE; HEXOBARBITAL; HYPNOTIC AGENT; IBUPROFEN; IMIPRAMINE; KETAMINE; LORCAINIDE; METHOHEXITAL; METHOXSALEN; MIDAZOLAM; NEUROLEPTIC AGENT; PROPAFENONE; QUINIDINE; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL; ZOLPIDEM;

ACCURACY; ARTICLE; DRUG BINDING; DRUG CLEARANCE; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN BINDING;

ATMOSPHERIC PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HALF-LIFE; HUMANS; MASS SPECTROMETRY; MICROSOMES, LIVER; PHARMACOKINETICS;

EID: 0032733974     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Abernathy DR, Greenblatt DJ and Shader RI (1985) Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 232:183-188.
2. Bachmann K (1987) Estimating the clearance of amylobarbitone from a single plasma measurement. Br J Clin Pharmacol 23:94-98.
3. Balant L (1981) Clinical pharmacokinetics of sulfonylurea hypoglycemic drugs. Clin Pharmacokinet 6:215-241.
4. Billard V, Gambou PL, Barr J, Minto CF, Corash L, Tessman JW, Stickner JL and Shafer SL (1995) The pharmacokinetics of 8-methoxypsoralen following iv administration in humans. Br J Clin Pharmacol 40:347-360.
5. Blyden GT, Greenblatt DJ, Scavone JM and Shader RI (1986) Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. J Clin Pharmacol 26:529-533.
6. Breimer DD (1976) Pharmacokinetics of methohexitone following intravenous infusion in humans. Br J Anaesth 48:643-649.
7. Breimer DD, Honhoff C, Zilly W, Richter E and von Rossum JM (1975) Pharmacokinetics of hexobarbital in man after intravenous infusion. J Pharmacokinet Biopharm 3:1-11.
8. Brosen K and Gram LF (1988) First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 43:400-406.
9. Bryson HM, Palmer KJ, Langtry HD and Fitton A (1993) Propafenone, a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 45:85-130.
10. Chan KKH, Vyas KH and Brandt KD (1987) In vitro binding of diclofenac sodium in plasma and synovial fluid. J Pharm Sci 76:105-108.
11. Cheng YF, Lundberg T, Bundesson U, Lindstrom L and Gabrielsson J (1988) Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 34:441-449.
12. Dahl SG and Strandjord RE (1974) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21:437-448.
13. Diederich S, Hanke B, Baehr V and Oelkers W (1996) The metabolism of 9a-fluorinated steroids in the human kidney. Endocr Res 22:803-810.
14. Durand A, Thenot JP, Bianchetti G and Morselli PL (1992) Comparative pharmacokinetic profile of two imidazopyridine drugs: Zolpidem and alpidem. Drug Metab Rev 24:239-266.
15. Echizen H and Eichelbaum M (1986) Clinical pharmacokinetics of verapamil, nifedipine, and diltiazem. Clin Pharmacokinet 11:425-449.
16. Eichelbaum M, Mikus G and Vogelsang D (1984) Pharmacokinetics of (+)-, (-)-, and (±)-verapamil after intravenous administration. Br J Clin Pharmacol 17:453-458.
17. Gardner MJ, Wilner KD, Hansen RA, Fouda HG and McMahon GF (1995) Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects. Br J Clin Pharmacol 39:11S-15S.
18. Gillis PP, DeAngelis RJ and Wynn RL (1976) Nonlinear pharmacokinetic model of intravenous anesthesia. J Pharm Sci 65:1001-1006.
19. Gobburu JVS and Shelver WH (1995) Quantitative structure-pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks. J Pharm Sci 84:862-865.
20. Greenblatt DJ, Allen MD, Harmatz JS and Shader RI (1980) Diazepam dispositional determinants. Clin Pharmacol Ther 27:301-312.
21. Greenblatt DJ, Pfeifer HJ, Ochs HR, Franke K, MacLaughlin DS, Smith TW and Kock-Weser J (1977) Pharmacokinetics of quinidine in humans after intravenous, intramuscular, and oral administration. J Pharmacol Exp Ther 202:365-378.
22. Heintz RC, Guentert TW, Enrico JF, Dubach UC, Brandt R, and Jeunet FS (1984) Pharmacokinetics of tenoxicam in healthy human volunteers. Eur J Rheum Influm 7:33-44.
23. Heizmann P, Eckert M and Ziegler WH (1983) Pharmacokinetics and bioavailability of midazolam. Br J Clin Pharmacol 16:S1-S199.
24. Hoener B (1994) Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm Drug Dispos 15:295-304.
25. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
26. Houston JB and Carlile DJ (1997) Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891-922.
27. Hughes IE, Ilett KF and Jellett LB (1975) The distribution of quinidine in human blood. Br J Clin Pharmacol 2:521-525.
28. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
29. Klotz U, Muller-Seydlitz P and Heimburg P (1978) Pharmacokinetics of lorcainide in man: A new antiarrythmic agent. Clin Pharmacokinet 3:407-418.
30. Kuhnz W and Gieschen H (1998) Predicting the oral bioavailability of 19-nortestosterone progestins in vivo from their metabolic stability in human liver microsomal preparations in vitro. Drug Metab Dispos 26:1120-1127.
31. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D and Coassolo P (1997a) Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590.
32. Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D and Coassolo P (1997b) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 14:152-155.
33. Lund A (1980) The distribution of chlorpromazine between plasma and erythrocytes. Acta Pharmacol Toxicol 47:300-304.
34. Maguire KP, Burrows GD, Norman TR, and Scoggins BA (1980) Blood/plasma distribution ratios of psychotropic drugs. Clin Chem 26:1624-1625.
35. Mahmood I (1998a) Interspecies scaling: Predicting volumes, mean residence time and elimination half-life. Some suggestions. J Pharm Pharmacol 50:493-499.
36. Mahmood I (1998b) Integration of in vitro data and brain weight in allometric scaling to predict clearance in humans: Some suggestions. J Pharm Sci 87:527-529.
37. Martin W, Koselowske G, Tobench H, Kerkmann T, Mangold B and Augustin J (1990) Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharm Drug Dispos 11:265-278.
38. Maxwell JD, Carella M, Parlies JD, Williams R, Mould GP and Curry SH (1972) Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis. Clin Sci 43:143-151.
39. Moreland TA and Hewick DS (1975) Sludies on a ketone reductase in human and rat liver and kidney soluble fraction using warfarin as a substrate. Biochem Pharmacol 24:1953-1957.
40. Obach RS (1996) The importance of non-specific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 24:1047-1049.
41. Obach RS (1997) Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-1369.
42. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
43. Omura T and Sato R (1964) The carbon monoxide binding pigment of liver microsomes. J Biol Chem 239:3137-3142.
44. O'Reilly PA (1972) Sodium warfarin. Pharmacology 8:181-190.
45. Peterson MC, Nation RL, McBride WG, Ashley JJ, and Moore RG (1983) Pharmacokinetics of betamethasone in healthy adults after intravenous administration. Eur J Clin Pharmacol 25:643-650.
46. Pibouin M, Zini R, Nguyen P and Renouard A (1987) Binding of 8-methoxypsoralen to human serum proteins and red blood cells. Br J Dermatol 117:207-215.
47. Rakhit A, Holford NHG, Guentert TW, Maloney K and Riegelman S (1984) Pharmacokinetics of quinidine and three of its metabolites in man. J Pharmacokinet Biopharm 12:1-21.
48. Rane A, Wilkinson GR and Shand DG (1977) Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 200:420-424.
49. Rodrigues AD (1997) Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. Pharm Res 14:1504-1510.
50. Rudy AC, Knight PM, Brater DC and Hall SD (1991) Stereoselective metabolism of ibuprofen in humans: Administration of R-, S-and racemic ibuprofen. J Pharmacol Exp Ther 259:1133-1139.
51. Sallee FR and Pollack BG (1990) Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 18:346-364.
52. Sarver JG, White D, Erhardt P and Bachmann K (1997) Estimating xenobiotic half-lives in humans from rat data: Influence of log P. Environ Health Persp 105:1204-1208.
53. Sawada Y, Hanano M, Sugiyama Y and Iga T (1985) Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J Pharmacokinet Biopharm 13:477-491.
54. Schalm SW, Summerskill WHJ and Go VLW (1977) Prednisone for chronic active liver disease: Pharmacokinetics, including conversion to prednisolone. Gastroenterology 72:910-913.
55. Schulz P, Turner Tamiyasu K, Smith G, Giacomini KM and Blaschke TF (1983) Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther 33:360-366.
56. Scott J and Poffenbarger PL (1979) Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 28:41-51.
57. Smith MS, Verghese CP, Shand DG and Pritchett ELC (1983) Pharmacokinetics and pharmacodynamic effects of diltiazem. Am J Cardiol 51:1364-1374.
58. Smith RB, Kroboth PD, Vanderlught JJ, Phillips JP and Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmology 84: 452-456.
59. Smith RB, Kroboth PD and Vamer PD (1987) Pharmacodynamics of triazolam after intravenous administration. J Clin Pharmacol 27:971-979.
60. Somani P, Frajer TD, Temesy-Armus PN (1987) Pharmacokinetic implications of lorcainide therapy in patients with normal and depressed cardiac function. J Clin Pharmacol 27:122-132.
61. Sutton D, Butler AM, Nadin L and Murray M (1997) Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 282:294-300.
62. Tomlinson ES, Lewis DFV, Maggs JL, Kroemer HK, Park BK and Back DJ (1997) The in vitro metabolism of dexamethasone (DEX) in human liver and kidney: The involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modeling studies. Biochem Pharmacol 54:605-611.
63. Tsuei SE, Moore RG, Ashley JJ and McBride WG (1979) Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. J Pharmacokinet Biopharm 7:249-264.
64. White PF, Schutter J, Shafer A, Stanski DR, Horai Y and Trevor AJ (1985) Comparative pharmacology of the ketamine isomers. Br J Anaesth 57:197-203.
65. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, and Welling PG (1979) The pharmacokinetics of diclofenac following intravenous and oral administration. Eur J Clin Pharmacol 16:405-410.